Previous 10 | Next 10 |
Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced the pricing of its initial public offering of 6,250,000 ...
Natural gas has been one of the worst-performing commodities over the last decade. However, the fundamentals are improving due to demand improving, and production being depressed. Reason one- Georgia will determine US energy policy Reason two- The rig count is low while the dema...
Satsuma Pharmaceuticals ( STSA -0.3% ) appointed industry veteran Thomas M. Soloway, currently serving as EVP and COO of Audentes Therapeutics ( BOLD ), to its board of directors, effective July 2, 2020. More news on: Satsuma Pharmaceuticals, Inc., Audentes Therapeutics, Inc., Asc...
Broadly, genetics is the study of genes, their variations and hereditary characteristics. As Live Science describes it , genetics involves looking at how traits are passed on through generations. So what is genetics investing? When it comes to genetics investing, companies in this niche li...
We've run through 10 different sectors or styles of investing in our year-end Marketplace Roundtable series. You can review the full list of roundtables at the end of this article in case you'd like to catch up on any specific angle. As we do every year, we conclude the series with the com...
NEW YORK, NY / ACCESSWIRE / January 3, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: MSB Financial Corp. (NASDAQ: MSBF ) ("MSB F...
NEW YORK, NY / ACCESSWIRE / December 27, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Audentes Therapeutics, Inc ( BOLD ) relat...
2019 finishes with an extra kick for investors. Part of that is the continued strong run of the market, erasing memories of last year's near bear market and extending the decade-long bull. There also are plenty of market headlines and events that have sprung over the end of the year, from Ph...
NEW YORK, Dec. 21, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Audentes Therapeutics, Inc. (NASDAQ: BOLD) The investigation concerns whether Audentes and its board of directors violated the federal se...
NEW YORK, NY / ACCESSWIRE / December 18, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Tiffany & Co. (NYSE: TIF ) relating t...
News, Short Squeeze, Breakout and More Instantly...
Audentes Therapeutics Inc. Company Name:
BOLD Stock Symbol:
NASDAQ Market:
Audentes Therapeutics Inc. Website:
Boundless Bio (Nasdaq: BOLD) , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer,...
BBI-355 Phase 1/2 POTENTIATE clinical trial ongoing; initiated targeted therapy combinations in patients with tumors with EGFR or FGFR oncogene amplifications First patient dosed in Phase 1/2 STARMAP clinical trial of BBI-825 in patients with tumors with resistance gene amplifications ...
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Boundless Bio Chief Financial Officer, Jami Rubin, will...